

Balnis et.al.

## **Higher plasma levels of chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes.**

**Authors:** Joseph Balnis<sup>1,2</sup>, Alejandro P. Adam<sup>1,3</sup>, Amit Chopra<sup>1</sup>, Hau C. Chieng<sup>1</sup>, Paul J. Feustel<sup>4</sup>, Katherine A. Overmyer<sup>5</sup>, Evgenia Shishkova<sup>6</sup>, Joshua J. Coon<sup>5,6</sup>, Harold A. Singer<sup>2</sup>, Marc A. Judson<sup>1</sup>, Ariel Jaitovich<sup>1,2\*</sup>

<sup>1</sup>Division of Pulmonary and Critical Care Medicine, <sup>2</sup>Department of Molecular and Cellular Physiology, <sup>3</sup>Ophthalmology and <sup>4</sup>Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, NY. <sup>5</sup>Morgridge Institute for Research, Madison, WI; <sup>6</sup>Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, WI

\*Address for reprint requests and other correspondence: A. Jaitovich, Albany Medical College, 47 New Scotland Ave., Albany, NY 12208 (e-mail: [jaitova@amc.edu](mailto:jaitova@amc.edu)).

**Funding:** Part of the results reported herein have been funded by NHLBI of the National Institutes of Health under the award number K01-HL130704 (AJ), and by the Collins Family Foundation Endowment (AJ); NIH/NHLBI 5R01HL049426 (HAS); NIH/National Institute of General Medical Sciences Grant 1R01GM124133 (APA); P41 GM108538 (KAO, ES, JJC).

Balnís et al.

**Abstract:** COVID19 pandemic has so far caused over three hundred thousand deaths worldwide, primarily due to complications from SARS-CoV-2-associated acute respiratory distress syndrome (ARDS). While an ARDS-driven hyperinflammatory phenotype is associated with higher mortality in non-COVID patients, there is little information on how cytokines and chemokines expressions correlate with clinical outcomes in COVID19 patients. We prospectively enrolled a cohort of 41 patients with acute respiratory distress syndrome on mechanical ventilation. Patients' blood was obtained at enrollment and outcome measures were liberation from mechanical ventilation and hospital-free days. We determined the expression levels of 44 circulating cytokines/chemokines and found 13 of them associated with worse outcomes. After correcting for multiple comparisons/false discovery rate, only one chemokine (CCL19) remained significantly associated with outcomes ( $p=0.009$ ). Although not described in association with COVID19, this chemokine was previously found elevated in an animal model of SARS-CoV. Moreover, CCL19 seems to be relevant for bronchus-associated lymphoid tissue (BALT) maintenance and for lung immunity to influenza virus. While this finding requires corroboration, CCL19 determination could facilitate early identification of COVID19-ARDS patients at higher risk of death and be novel target for immunotherapy in this setting.

Balnis et.al.

**Introduction:** COVID19 pandemic has so far caused over three hundred thousand deaths worldwide, primarily due to complications from SARS-CoV-2-associated acute respiratory distress syndrome (ARDS)<sup>1</sup>. While an ARDS-driven hyperinflammatory phenotype is associated with higher mortality in non-COVID patients<sup>2</sup>, there is little information on how cytokines and chemokines expressions correlate with clinical outcomes in COVID19 patients<sup>1</sup>. Indeed, emerging evidence suggests that there is a novel and complex inflammatory signature in COVID19-associated ARDS that is not found in other patients with ARDS<sup>3</sup>. While the general cytokine profile of COVID19 patients was recently reported<sup>4</sup>, there is no data about the association of circulating cytokine expression with ICU outcomes. In this study, we interrogated the cytokine/chemokine profile of COVID19-driven ARDS patients and hypothesized that a unique circulating signature would be associated with worse outcomes. **Methods:** We conducted a prospective cohort study involving 41 patients with diagnoses of COVID19 who required mechanical ventilation due to ARDS and were admitted to the Intensive Care Unit (ICU) of Albany Medical Center in New York between March 20 and April 17, 2020. Ethical approval was obtained from Albany Medical College Committee on Research Involving Human Subjects (IRB# 5670-20). Patients were considered for enrollment if they were older than 18 years and were admitted to the ICU for invasive mechanical ventilation due to COVID19-associated respiratory distress. Exclusion criteria were imminent death or inability to provide consent, which was obtained from the patient or a legally authorized representative. The average age of the cohort was 59.9 years (IQR 50-71.5) and there was a significant male predominance (68.3%). Other patients baseline characteristics are presented in **Table 1**. At the time of enrollment, blood samples were obtained and immediately centrifuged for plasma fractionation. Samples were frozen for later cytokines/chemokines determinations using a Human XL Cytokine magnetic Luminex-Discovery Fixed Panel (R&D Systems #LKTM014) performed simultaneously in duplicates within a week of enrollment completion. The primary outcome variable was patients' liberation from mechanical ventilation at day 28 after enrollment. Patients who died or remained ventilated longer than 28 days were grouped together (group 1, worse outcome) and compared with the rest of the cohort (group 2, better outcome); secondary outcome measure was hospital-free days

Balnís et.al.

at day 30 post enrollment. **Results:** A total of 44 cytokines/chemokines were measured, and 13 were associated with the selected outcomes (**Figure 1-A**); complete dataset including covariables, outcomes and cytokines expressions can be found in <https://figshare.com/s/5602c77cd1b7559b1593>. After adjustment for multiple comparisons/false discovery rate (FDR), only one entity, Chemokine (C-C motif) ligand 19 (CCL19) also known as macrophage inflammatory protein-3-beta (MIP-3- $\beta$ ), remained significantly associated with worse outcomes (**Figure 1-B and C**). Higher CCL19 levels were also positively correlated with APACHE II ( $p < 0.001$ ,  $r^2 0.19$ ), SOFA ( $p < 0.001$ ,  $r^2 0.3$ ) and SAPS II ( $p = 0.0012$ ,  $r^2 0.24$ ) severity scores, and with patients' hypoxemia as reflected by the P/F ratio ( $p = 0.0025$ ,  $r^2 0.21$ ), suggesting that it was a measure of COVID19 disease burden. **Discussion:** Here, we describe a complex cytokine/chemokine landscape associated with COVID19-ARDS and show that higher CCL19 plasma expression is significantly associated with worse outcomes. Although to our knowledge CCL19 plasma expression has not yet been reported in the context of COVID19 infection, higher expression was previously found in a ferret model of SARS-CoV infection<sup>5</sup>; and also associated with human immunodeficiency virus (HIV) infection progression and viral load<sup>6</sup>. Importantly, while CCL19 regulates the formation of bronchus-associated lymphoid tissue (BALT)<sup>7</sup>, its pulmonary expression was shown to be necessary to support local immunity in response to influenza virus infection<sup>8</sup>. Although our finding requires corroboration, we believe circulating levels of CCL19 from patients with severe COVID19 infection could have important implications, both as a biomarker of poor prognosis, and as a potential therapeutic target for immune modulation strategies focused on the COVID19 patients developing respiratory failure. Moreover, other cytokines found associated with the main outcome could, if confirmed, provide important insight into the mechanism regulating COVID19-associated respiratory failure and mortality.

**Conclusion:** Elevated CCL19 levels predict worse outcomes in a prospective cohort of COVID19 patients suffering from ARDS and on mechanical ventilation. This finding requires corroboration and

Balnis et.al.

could lead to the identification of an early biomarker of worse outcome, and a potential target to influence disease course.

**Table Legend:** Patients baseline characteristics in the whole cohort. Comparison of clinical and laboratory variables between patients in the group with better and worse outcomes, defined as ability to be liberated from mechanical ventilation at day 28 after enrollment. Data are presented as median with interquartile range (IQR); unless otherwise indicated. APACHE II: Acute Physiology and Chronic Health Evaluation II; SAPS II: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment. ECMO: Extracorporeal membrane oxygenation; CRP: C-reactive protein. Significant  $p$  values are indicated in bold font.

**Figure Legend:** **A:** Bar graph representing the cytokines/chemokines associated with the main outcome measure, and the directionality of the regulation (red, increased in the worse outcome group, blue, decreased in the worse outcome group). These associations were found to have a  $p$  value of  $<0.05$  before correcting for multiple comparisons/false discovery rate. Analysis was done with ANOVA test. **B:** After adjusting for multiple comparisons and false discovery rate, only CCL19 remained significantly associated with the main outcome. **C:** Comparison of CCL19 detected quantities between group 1 (worse outcome) versus group 2 (better outcome). \*\*  $p=0.009$

## References

- 1 Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*, doi:10.1056/NEJMoa2002032 (2020).
- 2 Calfee, C. S. et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. *Lancet Respir Med* **6**, 691-698, doi:10.1016/S2213-2600(18)30177-2 (2018).
- 3 Gattinoni, L., Chiumello, D. & Rossi, S. COVID-19 pneumonia: ARDS or not? *Crit Care* **24**, 154, doi:10.1186/s13054-020-02880-z (2020).
- 4 Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).

Balnis *et al.*

- 5 Danesh, A. *et al.* Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. *Virology* **409**, 102-112, doi:10.1016/j.virol.2010.10.002 (2011).
- 6 Damas, J. K. *et al.* Enhanced levels of the CCR7 ligands CCL19 and CCL21 in HIV infection: correlation with viral load, disease progression and response to highly active antiretroviral therapy. *AIDS* **23**, 135-138, doi:10.1097/QAD.0b013e32831cf595 (2009).
- 7 Fleige, H. *et al.* Manifold Roles of CCR7 and Its Ligands in the Induction and Maintenance of Bronchus-Associated Lymphoid Tissue. *Cell Rep* **23**, 783-795, doi:10.1016/j.celrep.2018.03.072 (2018).
- 8 Rangel-Moreno, J., Moyron-Quiroz, J. E., Hartson, L., Kusser, K. & Randall, T. D. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. *Proc Natl Acad Sci U S A* **104**, 10577-10582, doi:10.1073/pnas.0700591104 (2007).

Balnís et al.

<b>Table 1: Baseline characteristics of the cohort of</b>				
<b>Variables</b>	<b>Entire cohort</b>	<b>&gt;0 Ventilatory-free days Better outcome</b>	<b>0 Ventilatory-free days Worse outcome</b>	<b>p Value</b>
<b>Sex- N (%)</b>	n=41	n=22	n=19	
Male	28 (68.3%)	15 (68.2%)	13 (68.4%)	0.98
Female	13 (31.7%)	7 (31.8%)	6 (31.6%)	0.98
<b>Age (IQR)</b>	59.9 (50-71.5)	58.7 (53-67)	61.2 (46-73)	0.58
<b>Ethnicity- N (%)</b>				
White	11 (26.8%)	7 (31.8%)	4 (21.1%)	0.44
African American	5 (12.2%)	1 (4.5%)	4 (21.1%)	0.11
Asian	2 (5.9%)	1 (4.5%)	1 (5.3%)	0.91
Hispanic	13 (31.7%)	5 (22.7%)	8 (42.1%)	0.18
Other	10 (24.4%)	8 (36.4%)	2 (10.5%)	0.06
<b>Comorbidities- N(%)</b>				
Congestive heart failure	1 (2.4%)	1 (4.5%)	0 (0%)	0.35
Pulmonary disease	6 (14.6%)	5 (22.7%)	1 (5.3%)	0.11
Diabetes Mellitus	16 (39.1%)	9 (40.9%)	7 (36.8%)	0.79
renal Disease	4 (9.8%)	1 (4.5%)	3 (15.8%)	0.23
Cancer	2 (4.9%)	1 (4.5%)	1 (5.3%)	0.91
HIV/AIDS	1 (2.4%)	1 (4.5%)	0 (0%)	0.35
Charlson score index	3.05 (1-4)	3.09 (2-3.25)	3.00 (1-5)	0.90
<b>Severity scores (IQR)</b>				
APACHEII	24.17 (18.5-28.5)	21.45 (17.75-25.5)	27.32 (23-33)	<b>&lt;0.01</b>
SAPS II	59.85 (50.5-68.5)	56.23 (49.5-59)	64.05 (58-74)	<b>0.03</b>
SOFA	9.54 (7-12)	8.5 (6.75-10.25)	10.74 (7-13)	<b>0.04</b>
<b>Biomarkers (IQR)</b>				
Ferritin (NG/mL)	895.33 (376.5-1259)	724.91 (349.25-901.25)	1103.61 (685.75-1329)	0.07
CRP (MG/L)	179.31 (73.1-256.5)	170.81 (60.78-255.8)	190.32 (103.95-258.55)	0.59
D-dimer (MG/L FEU)	21.93 (2.12-25.65)	13.71 (1.66-19.03)	31.45 (4.11-56.27)	<b>0.05</b>
Procalcitonin (NG/mL)	6.35 (0.473-4.34)	6.43 (0.19-2.37)	6.27 (0.825-7.205)	0.97
Lactate (mmol/ L)	1.25 (0.905-1.51)	1.25 (0.87-1.56)	1.26 (0.92-1.39)	0.94
Fibrinogen (MG/DL)	556.53 (411.5-685.75)	555.9 (387-708)	557.2 (429.5-685.75)	0.98
<b>Respiratory variables (IQR)</b>				
P/F Ratio (ml/cmH <sub>2</sub> O)	159.15 (98-202.5)	187.5 (125.75-224)	126.4 (81-156)	<b>&lt;0.01</b>
Static Compliance (Torr)	41.05 (28.38-45.1)	42.19 (29.88-45.05)	39.72 (28-45.27)	0.70
<b>Treatment- N (%)</b>				
ECMO	2 (4.9%)	1 (4.5%)	1 (5.3%)	0.91
Antibiotics	41 (100%)	22 (100%)	19 (100%)	NA
Hydroxychloroquine	38 (92.7%)	21(95.5%)	17(89.5%)	0.47
Antiviral	1 (2.4%)	1 (4.5%)	0 (0%)	0.35
IL6- Antagonist	2 (4.9%)	0 (0%)	2 (10.5%)	0.12
Convalescent Plasma	16 (39.1%)	7 (31.8%)	9(47.4%)	0.31
Steroids	28 (68.3%)	17 (77.3%)	11 (57.9%)	0.18
<b>Outcome Mean (IQR)</b>				
28-day vent free day	8.71 (0-19)	16.23 (10.5-22.25)	NA	<b>&lt;0.0001</b>
30-day hospital free day	4.15 (0-8.5)	7.32 (0-12.5)	NA	<b>&lt;0.001</b>

# Figure

